FDA Delays Final OK for Type 2 Drug Empagliflozin

| Mar 23, 2014

The FDA will delay allowing the type 2 drug empagliflozin to enter the U.S. market until "previously observed deficiencies" at the plant where it is manufactured are fixed.

The delay does not call into question the safety or utility of the drug, which is manufactured by Eli Lilly and Boehringer Ingelheim.

Empagliflozin is an SGLT-2 inhibitor that has already been shown in clinical trials to successfully decrease weight and reduce A1c's in type 2 patients.

SGLT-2 (sodium glucose co-transporter-2) inhibitors are a fairly recent class of diabetes drugs to enter the U.S. and European markets. Unlike type 2 drugs that work by stimulating insulin production or reducing glucose production, SGLT-2 inhibitors work by making the kidneys shunt glucose into the urinary system rather than back into the bloodstream.

To date, the FDA has approved two SGLT-2 inhibitors for sale in the United States: FARXIGA (dapagliflozin), manufactured by AstraZeneca and Bristol-Meyers Squibb; and Invokana (canagliflozin) from Jansen.

Lilly and Boehringer Ingelheim have said they will work as quickly as possible to resolve the manufacturing plant issues. After that, it appears that empagliflozin could soon enter the U.S. market.

 

Click Here To View Or Post Comments

Categories: AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Canagliflozin, Dapagliflozin , Eli Lilly, Empagliflozin, Farxiga, FDA, Invokana, Jansen, SGLT-2 Inhibitors


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.